Abstract
The COVID-19 pandemic has had a terrible toll in terms of mortality and overwhelming health care systems worldwide. The race to handle the disease had precipitated research on both repurposed drugs as well as the development of new ones. There is biological plausibility for cyproheptadine to be useful as an anti-serotonergic agent. In this retrospective case series, we show that cyproheptadine has no significant side effects in a monitored setting that would preclude a larger trial to be done to assess potential therapeutic efficacy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
